Rafivirumab, formerly designated CR57, represents a novel agent targeting VEGF receptor 2 , VEGFR2. Its path from early research involved a substantial commitment by Nektar , followed by acquisition with Celgene. The therapeutic assessment has featured several phase assessments, mainly focusing on i